Dashboard
Manage Tickers

PLX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

protalix-biotherapeutics-unit-requests-reexamination-of-negative-opinion-issued-by-chmp-related-to-proposed-dosing-regimen-of-2-mgkg-body-weight-infused-every-4-weeks-for-elfabrio
Protalix BioTherapeutics Unit Requests Ree...
11/03/2025 21:33:09

Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc. (NYSE American: PLX), have...

why-is-protalix-biotherapeutics-stock-falling-on-friday
Why Is Protalix BioTherapeutics Stock Fall...
10/17/2025 15:23:15

EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data ...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
10/17/2025 12:13:10

protalix-biotherapeutics-says-chmp-denies-approval-for-every-4-week-elfabrio-regimen-in-eu-maintains-2-week-dosing-status-quo
Protalix BioTherapeutics Says CHMP Denies ...
10/17/2025 11:03:02

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/02/2025 21:06:15

protalix-biotherapeutics-q2-sales-15658m-beat-13546m-estimate
Protalix BioTherapeutics Q2 Sales $15.658M...
08/14/2025 10:51:53

Protalix BioTherapeutics (AMEX:PLX) reported quarterly sales of $15.658 million which beat the analyst consensus estimate of $1...

Core News & Articles
Earnings Scheduled For August 14, 2025
08/14/2025 08:32:32

preview-protalix-biotherapeuticss-earnings
Preview: Protalix BioTherapeutics's Earnings
08/13/2025 17:02:31

protalix-biotherapeutics-appoints-gilad-mamlok-as-svp-and-cfo-effective-august-24-2025-succeeding-eyal-rubin
Protalix BioTherapeutics Appoints Gilad Ma...
07/21/2025 10:51:50

protalix-biotherapeutics-added-to-russell-3000-and-russell-2000-indexes-effective-june-27-2025-as-part-of-2025-russell-indexes-annual-reconstitution
Protalix BioTherapeutics Added To Russell ...
06/30/2025 10:52:45

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
05/09/2025 12:10:06

protalix-biotherapeutics-q1-eps-005-misses-003-estimate-sales-1011m-miss-2160m-estimate
Protalix BioTherapeutics Q1 EPS $(0.05) Mi...
05/09/2025 10:53:23

Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate ...

Core News & Articles
Earnings Scheduled For May 9, 2025
05/09/2025 08:32:15

uncovering-potential-protalix-biotherapeuticss-earnings-preview
Uncovering Potential: Protalix BioTherapeu...
05/08/2025 18:02:54

protalix-biotherapeutics-says-with-debt-fully-repaid-its-well-positioned-to-execute-strategy-through-2025-and-beyond
Protalix BioTherapeutics Says With Debt Fu...
03/17/2025 15:56:28

Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start ...

protalix-biotherapeutics-fy-2024-gaap-eps-004-beats-001-estimate-sales-5340m-miss-5394m-estimate
Protalix BioTherapeutics FY 2024 GAAP EPS ...
03/17/2025 11:00:39

Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of...

earnings-scheduled-for-march-17-2025
Earnings Scheduled For March 17, 2025
03/17/2025 08:32:11

hc-wainwright--co-maintains-buy-on-protalix-biotherapeutics-raises-price-target-to-15
HC Wainwright & Co. Maintains Buy on Prota...
02/03/2025 11:51:18

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Protalix BioTherapeutics (AMEX:PLX) with a Buy and raises the p...

chiesi-global-rare-diseases-a-business-unit-of-the-chiesi-and-protalix-biotherapeutics-announced-that-the-european-medicines-agency-has-validated-the-variation-submission-for-pegunigalsidase-alfa-to-label-a-less-frequent-dosing-regimen
Chiesi Global Rare Diseases, A Business Un...
12/09/2024 11:47:24

Chiesi Global Rare Diseases, a business unit of the Chiesi and Protalix BioTherapeutics announced that the European Medicines A...

protalix-biotherapeutics-q3-2024-gaap-eps-003-misses-006-estimate-sales-1796m-beat-1626m-estimate
Protalix BioTherapeutics Q3 2024 GAAP EPS ...
11/14/2024 11:54:44

Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION